Literature DB >> 7577475

Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.

A M Cleton-Jansen1, N Collins, S R Lakhani, J Weissenbach, P Devilee, C J Cornelisse, M R Stratton.   

Abstract

Loss of heterozygosity (LOH) on chromosome 13 occurs on 25-30% of breast tumours. This may reflect the inactivation of the retinoblastoma susceptibility gene RB1. However, recently another candidate tumour-suppressor gene has been identified on chromosome 13 by linkage analysis, the breast cancer susceptibility gene BRCA2. To investigate the involvement of BRCA2 in sporadic breast cancer 200 breast tumours were tested for LOH on chromosome band 13q12-q14, using 11 highly polymorphic microsatellite markers. LOH was found in 65 tumours, which all showed simultaneously loss of BRCA2 and RB1. Of 12 breast tumour cell lines tested with polymorphic microsatellite markers, seven showed a contiguous region of homozygosity on 13q12-q14, suggesting LOH in the tumour from which the cell line had been derived. One cell line showed homozygosity in the BRCA2 region and heterozygosity at RB1. This is the only indication that BRCA2 is a distinct target for LOH on chromosome 13 in addition to RB1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577475      PMCID: PMC2033960          DOI: 10.1038/bjc.1995.493

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours.

Authors:  J M Varley; J Armour; J E Swallow; A J Jeffreys; B A Ponder; A T'Ang; Y K Fung; W J Brammar; R A Walker
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

2.  Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus.

Authors:  M K Dodson; W A Cliby; H J Xu; K A DeLacey; S X Hu; G L Keeney; J Li; K C Podratz; R B Jenkins; W F Benedict
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

3.  Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression.

Authors:  T M Kim; W F Benedict; H J Xu; S X Hu; J Gosewehr; M Velicescu; E Yin; J Zheng; G D'Ablaing; L Dubeau
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

4.  Instability of short tandem repeats (microsatellites) in human cancers.

Authors:  R Wooster; A M Cleton-Jansen; N Collins; J Mangion; R S Cornelis; C S Cooper; B A Gusterson; B A Ponder; A von Deimling; O D Wiestler
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

5.  Structural rearrangement of the retinoblastoma gene in human breast carcinoma.

Authors:  A T'Ang; J M Varley; S Chakraborty; A L Murphree; Y K Fung
Journal:  Science       Date:  1988-10-14       Impact factor: 47.728

Review 6.  Recent developments in the molecular genetic understanding of breast cancer.

Authors:  P Devilee; E Schuuring; M J van de Vijver; C J Cornelisse
Journal:  Crit Rev Oncog       Date:  1994

7.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13.

Authors:  N Collins; R McManus; R Wooster; J Mangion; S Seal; S R Lakhani; W Ormiston; P A Daly; D Ford; D F Easton
Journal:  Oncogene       Date:  1995-04-20       Impact factor: 9.867

8.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers.

Authors:  E Y Lee; H To; J Y Shew; R Bookstein; P Scully; W H Lee
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

9.  Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL.

Authors:  P Devilee; E M van Schothorst; A F Bardoel; B Bonsing; N Kuipers-Dijkshoorn; M R James; G Fleuren; A G van der Mey; C J Cornelisse
Journal:  Genes Chromosomes Cancer       Date:  1994-10       Impact factor: 5.006

10.  Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity.

Authors:  E C Abeln; W E Corver; N J Kuipers-Dijkshoorn; G J Fleuren; C J Cornelisse
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  21 in total

Review 1.  BRCA1 and BRCA2 proteins: roles in health and disease.

Authors:  J A Duncan; J R Reeves; T G Cooke
Journal:  Mol Pathol       Date:  1998-10

2.  The D13S171 marker, misannotated to BRCA2, links the AS3 gene to various cancers.

Authors:  P Geck; C Sonnenschein; A M Soto
Journal:  Am J Hum Genet       Date:  2001-08       Impact factor: 11.025

3.  A somatic truncating mutation in BRCA2 in a sporadic breast tumor.

Authors:  B H Weber; M Brohm; I Stec; J Backe; H Caffier
Journal:  Am J Hum Genet       Date:  1996-10       Impact factor: 11.025

4.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Authors:  S Håkansson; O Johannsson; U Johansson; G Sellberg; N Loman; A M Gerdes; E Holmberg; N Dahl; N Pandis; U Kristoffersson; H Olsson; A Borg
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

5.  Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator.

Authors:  P Geck; M V Maffini; J Szelei; C Sonnenschein; A M Soto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

7.  ATR inhibition preferentially targets homologous recombination-deficient tumor cells.

Authors:  M Krajewska; R S N Fehrmann; P M Schoonen; S Labib; E G E de Vries; L Franke; M A T M van Vugt
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

8.  A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.

Authors:  A Arason; A Jonasdottir; R B Barkardottir; J T Bergthorsson; M D Teare; D F Easton; V Egilsson
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

9.  Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.

Authors:  Goutam Chakraborty; Joshua Armenia; Ying Z Mazzu; Subhiksha Nandakumar; Konrad H Stopsack; Mohammad O Atiq; Kazumasa Komura; Lina Jehane; Rahim Hirani; Kalyani Chadalavada; Yuki Yoshikawa; Nabeela A Khan; Yu Chen; Wassim Abida; Lorelei A Mucci; Gwo-Shu Mary Lee; Gouri J Nanjangud; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2019-12-03       Impact factor: 12.531

10.  Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

Authors:  B A Carneiro; K A Collier; R J Nagy; S Pamarthy; V Sagar; S Fairclough; J Odegaard; R B Lanman; R Costa; T Taxter; T M Kuzel; A Fan; Y K Chae; M Cristofanilli; M H Hussain; S A Abdulkadir; F J Giles
Journal:  JCO Precis Oncol       Date:  2018-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.